Pain & Inflammation;

• The CB2 receptor and its role as a regulator of inflammation (Cell Mol Life Sci. 2016; 73(23): 4449-70.)
• Targeting CB2 receptors and the endocannabinoid system for the treatment of pain (Brain Res Rev. 2009 Apr; 60(1): 255-266.)
• Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain (Br J Pharmacol. 2008 Jan; 153(2): 319–334.)
• The central cannabinoid receptor type-2 (CB2) and chronic pain. (Int J Neurosci. 2017 Sep;127(9):812-823.)

• Anxiety

  • Anxious behavior induces elevated hippocampal CB2 expression. (Neuroscience. 2017 Jun 3;352:273-284.)
  • Regulatory role of the CB2 receptor in stress-induced neuroinflammation. (Br J Pharmacol. 2014 Jun;171(11):2814-26.)

  • Degenerative neurological conditions

    • Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders (Front Neurosci. 2016; 10: 406.)
    • Central CB2 receptors in inflammation-driven neurodegeneration: dysregulation and therapeutic potential (Neural Regen Res. 2016 Sep; 11(9): 1409–1410.)
    • CB2 receptor: Potential role in immunomodulation and neuroinflammation (J Neuroimmune Pharmacol. 2013 Jun; 8(3): 608-620.)

    • Cannabinoid CB2 receptors in human brain inflammation (Br J Pharmacol. 2008 Jan; 153(2): 277–285.)

    • Multiple Sclerosis:

      • CB2 receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies (Br J Pharmacol. 2008 Jan; 153(2): 216–225.)

      • Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis. (J Neuroimmunol. 2017 Feb 15;303:66-74.)

      • Alzheimer s Disease

        • CB2 cannabinoid receptor as potential target against Alzheimer’s Disease (Front Neurosci. 2016; 10: 243.)

        • Parkinson s Disease

          • Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson’s Disease (Front Neurosci. 2016; 10: 321.)
          • CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease (Exp Mol Med. 2016 Jan; 48(1): e205.)

          • Osteoarthritis:

            • Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint (PLoS One. 2013; 8(11): e80440.)
            • Expression of cannabinoid receptors in human osteoarthritic cartilage: Implications for future therapies (Cannabis Cannabinoid Res. 2016 Jan 1;1(1):3-15)

            • Rheumatoid arthritis:

              • CB2 as a potential therapeutic target in rheumatoid arthritis (Musculoskeletal Disorders. 2014; 15: 275.)

              • CB2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis (Rheumatology. 2014; 53(5): 802-809.)

              • Role of CB2 in mediating inflammation in rheumatoid arthritis synovial fibroblasts. (Clin Exp Rheumatol. 2019 Nov-Dec;37(6):1026-1035.)

              • Immune system modulation:

                • CB2: Potential role in immunomodulation and neuroinflammation (J Neuroimmune Pharmacol. 2013 Jun; 8(3): 608-620.)
                • Emerging role of the CB2 cannabinoid receptor in immune regulation and therapeutic prospects (Expert Rev Mol Med. 2009 Jan 20; 11: e3.)

                • Cardiovascular:

                  • CB2 drives neurogenesis and improves functional outcome after stroke (Stroke. 2017 Jan;(48)1:204-212.)

                  • Prospects for creation of cardioprotective drugs based on cannabinoid receptor agonists (J Cardiovasc Pharmacol Ther. 2016 May;21(3):262-72.)
                  • CB2 in atherosclerosis and acute cardiovascular diseases (Curr Med Chem. 2014;(21)35:4046-58.)

                  • CB2 receptor stimulation attenuates the initiation and progression of atherosclerosis. (Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2210-8.)

                  • Time-Dependent Protection of CB2 Receptor Agonist in Stroke. (PLoS One. 2015 Jul 17;10(7):e0132487.)
                  • Selective Modulator of CB2 Reduces Memory Impairment and Infarct Size During Cerebral Hypoperfusion and Vascular Dementia. (Curr Neurovasc Res. 2016;13(4):289-302.)
                  • The Endocannabinoid System and Heart Disease: The Role of CB2. (Cardiovasc Hematol Disord Drug Targets. 2018;18(1):34-51.)

                  • Metabolic Disorders:

                    • CB2 receptor agonist improves systemic sensitivity to insulin (Cell Physiol Biochem. 2016;40(5):1175-1185.)

                    • Anti-Obesity Effect of a CB2 Receptor Agonist in Diet-Induced Obese Mice. (PLoS One. 2015 Nov 20;10(11):e0140592.)

                    • Digestive Disorders:

                      • CB2 receptor-induced relief of hypermotility in a rat model of the irritable bowel syndrome (Neurogastroenterol Motil. 2019 Jun;31(6):e13613.)

                      • Cannabinoids and intestinal motility: welcome to CB2 receptors. (Br J Pharmacol. 2004 Aug;142(8):1201-2.)

                      • Migraine:

                        • Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model (J Headache Pain. 2014; 15(1): 14.)

                        • Eye Health

                          • Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye. Prostaglandins Other Lipid Mediat. 2018 Nov;139:54-62.
                          • CB2 receptors are upregulated with corneal injury and regulate the course of corneal wound healing. Exp Eye Res. 2019 May;182:74-84.

                          • Activation of CB2 by selective agonists regulates the deposition and remodelling of the extracellular matrix. Biomed Pharmacother. 2017 Nov;95:1704-1709.
                          • CB2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy. Neuropharmacology. 2017 Feb;113(Pt B):627-638.

                          • CB2 receptor activation reduces leukocyte adhesion and improves capillary perfusion in the iridial microvasculature during systemic inflammation. Clin Hemorheol Microcirc. 2015;61(2):237-49.

                          • Skin Health:

                            • CB2 exerts antifibrotic effects in experimental dermal fibrosis. (Arthritis Rheum. 2009 Apr;60(4):1129-36.)

                            • Respiratory Health:

                              • CB2 agonist prevents nicotine induced lung fibrosis. (Exp Lung Res. 2018 Sep;44(7):344-351.)

                              • 
                                Enhance your CBD Experience

                                As mentioned, CB2™ can greatly enhance the benefits you already receive from CBD products. Here s how:

                                • Activating CB2 receptors is not how CBD is thought to work. This is because CBD only has a very weak ability to bind to CB2 receptors.
                                • Newer studies suggest CBD may influence cannabinoid receptor shape and or inhibit the proteins that remove our endocannabinoids. This means our own endocannabinoids can then activate CB2 receptors, and could be how we get the benefits from CBD products.
                                • However, if we can supply the body with external sources of compounds that directly activate CB2 receptors (such as those found in our CB2™ Hemp Seed Oil, we can amplify those benefits. It s actually the perfect combination!
                                • Even better, CB2™ Hemp Seed Oil version provides the exact essential fatty acids that our bodies use to create more of our own endocannabinoids!

                                • Ingredients

                                  Organic hemp seed oil, Cannanda CB2™ terpene blend (100% natural terpenes extracted from botanical sources), tapioca starch, curcumin, vegetable glycerin, purified water
                                  
                                  Contains NO: wheat gluten, dairy lactose, soy, corn, sugar, GMO, carrageenan, articial flavours or colours.

                                  
                                  

                                  Directions for Use:

                                  Adults: Take 2-5 softgels 1-3 times daily, with food, or as directed by your healthcare practitioner. To find the dose that s best for your body, start at the lower end of the range, and slowly increase the number of softgels per day until you find your ideal dose.